Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
X-linked microcephaly-growth retardation-prognathism-cryptorchidism syndrome is a rare syndromic intellectual disability characterized by hypotonia, microcephaly, severe developmental delay, seizures, intellectual disability, growth retardation, cardiovascular septal defects, cryptorchidism, hypospadias, and dysmorphic features - prominent ears, prognathism, thin upper lip, dental crowding.
Features include always present findings: Cryptorchidism, Microcephaly, Mandibular prognathia, and Seizure and others; and common findings: Thin upper lip vermilion, Hypospadias, Inner ear hearing loss (sensorineural hearing impairment), and Protruding ear and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Head and neck | 4 | Thin upper lip vermilion, Microcephaly, Mandibular prognathia |
Biomarker and diagnostic research for X-linked microcephaly-growth retardation-prognathism-cryptorchidism syndrome has been reported in the published literature.
1 FDA-approved treatment is available for X-linked microcephaly-growth retardation-prognathism-cryptorchidism syndrome, including somatropin (Nutropin, approved 1993).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
Phenotype severity distribution: 9 always present features, 16 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for X-linked microcephaly-growth retardation-prognathism-cryptorchidism syndrome.
200 publications have been identified in PubMed for X-linked microcephaly-growth retardation-prognathism-cryptorchidism syndrome. Research spans Review / Meta-Analysis (42%), Basic Science / Preclinical (22%), and Case Report / Case Series (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 72 | 42% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 9:32 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about X-linked microcephaly-growth retardation-prognathism-cryptorchidism syndrome
Muscles |
3 |
Low muscle tone (hypotonia), Knee flexion contracture, Ankle flexion contracture |
Brain and nerves | 2 | Seizure, Self-injurious behavior |
Arms and legs | 2 | Tapered finger, Finger syndactyly |
Digestive system | 1 | Gastroesophageal reflux |
Blood and immune system | 1 | Recurrent infections |
Growth and development | 1 | Severe postnatal growth retardation |
Ears | 1 | Inner ear hearing loss (sensorineural hearing impairment) |
Lungs and breathing | 1 | Pulmonary artery stenosis |
Nutropin
somatropin |
— |
1993 |
Available |
Gene therapy approaches for X-linked microcephaly-growth retardation-prognathism-cryptorchidism syndrome have been reported in the published literature.
View trials for X-linked microcephaly-growth retardation-prognathism-cryptorchidism syndrome
Laboratory research |
38 |
22% |
Patient case studies | 31 | 18% |
Disease patterns and progression | 17 | 10% |
Other research | 5 | 3% |
New treatment approaches | 5 | 3% |
Testing and diagnosis research | 3 | 2% |
Clinical study results | 1 | 1% |
Fryze M (2026). [PMID: 41743903](https://pubmed.ncbi.nlm.nih.gov/41743903/). *Clin Cosmet Investig Dermatol*. [Review / Meta-Analysis]
Parrett BJ (2026). [PMID: 41648584](https://pubmed.ncbi.nlm.nih.gov/41648584/). *bioRxiv*. [Gene Therapy / Novel Therapeutics]
Singh G (2026). [PMID: 30252248](https://pubmed.ncbi.nlm.nih.gov/30252248/). *Unknown Journal*. [Case Report / Case Series]
Bertin M (2026). [PMID: 41535291](https://pubmed.ncbi.nlm.nih.gov/41535291/). *Nat Commun*. [Basic Science / Preclinical]
Lin MH (2026). [PMID: 41183732](https://pubmed.ncbi.nlm.nih.gov/41183732/). *Kidney Int*. [Gene Therapy / Novel Therapeutics]
Beck DB (2026). [PMID: 41991535](https://pubmed.ncbi.nlm.nih.gov/41991535/). *Nat Rev Dis Primers*. [Review / Meta-Analysis]
Bin Shlhoob R (2026). [PMID: 32491315](https://pubmed.ncbi.nlm.nih.gov/32491315/). *Unknown Journal*. [Other]
Yuan L (2026). [PMID: 41507200](https://pubmed.ncbi.nlm.nih.gov/41507200/). *Nat Commun*. [Basic Science / Preclinical]
Hoff FW (2026). [PMID: 41531276](https://pubmed.ncbi.nlm.nih.gov/41531276/). *Br J Haematol*. [Review / Meta-Analysis]
Shah M (2026). [PMID: 29083768](https://pubmed.ncbi.nlm.nih.gov/29083768/). *Unknown Journal*. [Other]